FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080459529> ?p ?o ?g. }

• W3080459529 abstract "Abstract Background Type 2 diabetes is closely related to an increased risk of atrial fibrillation (AF) and atrial flutter (AFL). Whether sodium-glucose cotransporter 2 (SGLT2) inhibitors can attenuate AF/AFL progression remains unclear. Methods We searched electronic databases (PubMed, Embase and ClinicalTrials.gov) from their inception to January 2020 for trials evaluating the AF outcomes of SGLT2 inhibitors in patients with type 2 diabetes. The data search and extraction were conducted with a standardized data form and any conflicts were resolved by consensus. Relative risks (RRs) with 95% confidence intervals (CIs) were used for binary variables, and the weighed mean differences (WMDs) with the standard deviation (SDs) were applied for continuous variables. Results We included data from 16 identified trials consisting of 38,335 patients with type 2 diabetes. Incorporated data demonstrated that compared to placebo, SGLT2 inhibitors significantly reduced AF/AFL (RR: 0.76; 95% CI 0.65–0.90; p = 0.001) and all-cause mortality (RR: 0.91; 95% CI 0.83–0.99; p = 0.03). AF/AFL reductions were not modified by age, body weight, glycated haemoglobin (HbA1c), or systolic blood pressure (SBP) at baseline (all p-interactions > 0.3). SGLT2 inhibitors also significantly reduced heart failure events (RR: 0.73; 95% CI 0.64–0.84; p < 0.00001), HbA1c (WMD: − 0.62%; 95% CI − 0.89 to − 0.34; p < 0.00001), body weight (WMD: − 2.12 kg; 95% CI − 2.91 to − 1.34; p < 0.00001), SBP (WMD: − 3.34 mmHg; 95% CI − 4.12 to − 2.56; p < 0.00001), and diastolic blood pressure (DBP) (WMD: − 1.11 mmHg; 95% CI − 1.62 to − 0.60; p < 0.0001). Of note, cerebrovascular events and myocardial infarction did not increase in patients taking SGLT2 inhibitors. Conclusion SGLT2 inhibitors may confer a specific AF/AFL-reduction benefit in the susceptible type 2 diabetes population, regardless of age, body weight, HbA1c, and systolic blood pressure at baseline. Such an AF/AFL-reduction benefit may be partly attributed to pharmacological effects on reductions in HbA1c, body weight, blood pressure, and the occurrence of heart failure." @default.
• W3080459529 created "2020-09-01" @default.
• W3080459529 creator A5005087327 @default.
• W3080459529 creator A5012004938 @default.
• W3080459529 creator A5035633072 @default.
• W3080459529 creator A5048712705 @default.
• W3080459529 creator A5056630426 @default.
• W3080459529 date "2020-08-26" @default.
• W3080459529 modified "2023-10-03" @default.
• W3080459529 title "SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials" @default.
• W3080459529 cites W15581989 @default.
• W3080459529 cites W1847388060 @default.
• W3080459529 cites W1898894592 @default.
• W3080459529 cites W1921395120 @default.
• W3080459529 cites W1987553321 @default.
• W3080459529 cites W2031730303 @default.
• W3080459529 cites W2045790951 @default.
• W3080459529 cites W2051243940 @default.
• W3080459529 cites W2054361323 @default.
• W3080459529 cites W2057080587 @default.
• W3080459529 cites W2066466450 @default.
• W3080459529 cites W2074989651 @default.
• W3080459529 cites W2081510795 @default.
• W3080459529 cites W2100796772 @default.
• W3080459529 cites W2114031829 @default.
• W3080459529 cites W2125435699 @default.
• W3080459529 cites W2134833483 @default.
• W3080459529 cites W2139245232 @default.
• W3080459529 cites W2152413054 @default.
• W3080459529 cites W2444268874 @default.
• W3080459529 cites W2468961432 @default.
• W3080459529 cites W2572657306 @default.
• W3080459529 cites W2604277961 @default.
• W3080459529 cites W2619772777 @default.
• W3080459529 cites W2733530127 @default.
• W3080459529 cites W2753486080 @default.
• W3080459529 cites W2884466498 @default.
• W3080459529 cites W2887650349 @default.
• W3080459529 cites W2888632254 @default.
• W3080459529 cites W2899764361 @default.
• W3080459529 cites W2914546434 @default.
• W3080459529 cites W2939222610 @default.
• W3080459529 cites W2969786006 @default.
• W3080459529 cites W2976126564 @default.
• W3080459529 cites W2977176458 @default.
• W3080459529 cites W2978698783 @default.
• W3080459529 cites W2989603136 @default.
• W3080459529 cites W2995061256 @default.
• W3080459529 cites W2999533661 @default.
• W3080459529 cites W3004319546 @default.
• W3080459529 cites W3011855095 @default.
• W3080459529 doi "https://doi.org/10.1186/s12933-020-01105-5" @default.
• W3080459529 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7448518" @default.
• W3080459529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32847602" @default.
• W3080459529 hasPublicationYear "2020" @default.
• W3080459529 type Work @default.
• W3080459529 sameAs 3080459529 @default.
• W3080459529 citedByCount "73" @default.
• W3080459529 countsByYear W30804595292020 @default.
• W3080459529 countsByYear W30804595292021 @default.
• W3080459529 countsByYear W30804595292022 @default.
• W3080459529 countsByYear W30804595292023 @default.
• W3080459529 crossrefType "journal-article" @default.
• W3080459529 hasAuthorship W3080459529A5005087327 @default.
• W3080459529 hasAuthorship W3080459529A5012004938 @default.
• W3080459529 hasAuthorship W3080459529A5035633072 @default.
• W3080459529 hasAuthorship W3080459529A5048712705 @default.
• W3080459529 hasAuthorship W3080459529A5056630426 @default.
• W3080459529 hasBestOaLocation W30804595291 @default.
• W3080459529 hasConcept C126322002 @default.
• W3080459529 hasConcept C134018914 @default.
• W3080459529 hasConcept C142724271 @default.
• W3080459529 hasConcept C164705383 @default.
• W3080459529 hasConcept C168563851 @default.
• W3080459529 hasConcept C204787440 @default.
• W3080459529 hasConcept C27081682 @default.
• W3080459529 hasConcept C2777180221 @default.
• W3080459529 hasConcept C2778198053 @default.
• W3080459529 hasConcept C2779161974 @default.
• W3080459529 hasConcept C44249647 @default.
• W3080459529 hasConcept C555293320 @default.
• W3080459529 hasConcept C71924100 @default.
• W3080459529 hasConcept C82789193 @default.
• W3080459529 hasConcept C95190672 @default.
• W3080459529 hasConceptScore W3080459529C126322002 @default.
• W3080459529 hasConceptScore W3080459529C134018914 @default.
• W3080459529 hasConceptScore W3080459529C142724271 @default.
• W3080459529 hasConceptScore W3080459529C164705383 @default.
• W3080459529 hasConceptScore W3080459529C168563851 @default.
• W3080459529 hasConceptScore W3080459529C204787440 @default.
• W3080459529 hasConceptScore W3080459529C27081682 @default.
• W3080459529 hasConceptScore W3080459529C2777180221 @default.
• W3080459529 hasConceptScore W3080459529C2778198053 @default.
• W3080459529 hasConceptScore W3080459529C2779161974 @default.
• W3080459529 hasConceptScore W3080459529C44249647 @default.
• W3080459529 hasConceptScore W3080459529C555293320 @default.
• W3080459529 hasConceptScore W3080459529C71924100 @default.
• W3080459529 hasConceptScore W3080459529C82789193 @default.
• W3080459529 hasConceptScore W3080459529C95190672 @default.
• W3080459529 hasIssue "1" @default.

• next